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Summary  1 
Objective: The objective of the study was to investigate the percentage of dogs diagnosed with immune-2 
complex glomerulonephritis in the United Kingdom (UK), in a large cohort of dogs with clinical suspicion 3 
of glomerular disease where renal histopathology including routine light microscopy, transmission 4 
electron microscopy and immunofluorescence had been performed. The second objective of the study 5 
was to describe prescribed treatment and long-term clinical outcome of dogs diagnosed with immune-6 
complex glomerulonephritis.   7 
Methods: Sixty-two dogs originating from the UK who underwent renal biopsies for investigation of 8 
suspected glomerulopathy (urine protein-to-creatinine ratio persistently >0.5) were included in this 9 
retrospective multicentre study. Signalment, clinico-pathological abnormalities, histopathological 10 
diagnosis, treatment following diagnosis and survival were recorded. 11 
Results: Twenty-seven percent (17/62) of the population of dogs with suspected glomerular disease 12 
were diagnosed with immune-complex glomerulonephritis. Fifty-three percent (9/17) of dogs diagnosed 13 
with immune-complex glomerulonephritis were still alive at the study end point, with a median follow-up 14 
time of 366 days (range 52-1299). Six dogs diagnosed with immune-complex glomerulonephritis were 15 
treated with mycophenolate. Four received solely mycophenolate for immunosuppression and two 16 
received mycophenolate and chlorambucil, and all six were alive at data collection (median follow-up 17 
time 712.5 days (range 73-1299)). Seven dogs diagnosed with immune-complex glomerulonephritis did 18 
not receive immunosuppressive treatment, only one of these dogs was alive at study end point (median 19 
survival time 302 days (range 52-723)). 20 
Clinical relevance: Immune-complex glomerulonephritis may be less frequent in the UK than previously 21 
reported in North America and mainland Europe, reducing the likelihood of treatment modification 22 
following renal biopsy. Mycophenolate was the most commonly used immunosuppressant for cases of 23 
immune-complex glomerulonephritis.  24 
Key-words: immune-complex glomerulonephritis; dog; UK; mycophenolate; outcome; renal biopsy; 25 
kidney  26 
Word count (excluding summary and references): 3992  27 
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Introduction 28 
Glomerular disease is suspected in cases of persistent renal proteinuria (Urine Protein-to-Creatinine 29 
ratio (UPC) ≥0.5 in dogs) (Lees et al., 2005). Immune-complex glomerulonephritis (ICGN) is reported 30 
as the most common cause of proteinuria in dogs undergoing renal biopsy for suspected glomerular 31 
disease, with a prevalence of 48% in North America (Schneider et al., 2013) and 50% in European 32 
countries (Mainland Europe and UK altogether) (Aresu et al., 2017). Other common diagnoses include 33 
primary glomerulosclerosis (21%), amyloidosis (15%), other non-immune complex mediated 34 
glomerulopathies (9%), non-immune complex mediated nephropathies (5%) and primary 35 
tubulointerstitial disease (2%) (Schneider et al., 2013).  36 
The International Renal Interest Society (IRIS) proteinuria consensus statements recommend that dogs 37 
with ICGN should not only receive standard anti-proteinuric therapy (Brown et al., 2013), but should also 38 
receive immunosuppressive therapy comprised of one or more immunosuppressive drugs, once medical 39 
investigations have been performed to exclude possible underlying systemic disease  (Segev et al., 40 
2013). According to the IRIS proteinuria consensus statements, “Dogs with peracute or rapidly 41 
progressive glomerular disease should receive […] mycophenolate alone or in combination with 42 
prednisolone, or cyclophosphamide (continuous or pulse therapy) alone or in combination with 43 
prednisolone”, and “Dogs with active but stable or slowly progressive glomerular diseases with an 44 
immune-mediated foundation […] may receive […] mycophenolate, chlorambucil alone or in 45 
combination with azathioprine on alternating days, cyclophosphamide and glucocorticoids or 46 
cyclosporine” (Segev et al., 2013). 47 
The diagnosis of ICGN requires renal biopsy with evaluation by light microscopy (LM), transmission 48 
electron microscopy (TEM) and immunofluorescence (IF) (Cianciolo et al., 2013). Although renal biopsy 49 
procedures in dogs (by ultrasound-guided percutaneous approach, laparotomy or laparoscopy) are 50 
considered relatively safe, historically, complications are reported in up to 13% of cases with the most 51 
common complication being severe haemorrhage and death in 2.5% of cases (Vaden et al., 2005). The 52 
cost of taking and interpreting renal biopsies can be prohibitive for owners, as this procedure should be 53 
performed under general anaesthesia and samples should be collected, prepared and interpreted by 54 
specialised veterinary nephropathologists.  55 
Considering the percentage of dogs diagnosed with ICGN in North America and in Europe, and the 56 
specific treatment recommendations made for ICGN management, it appears that performing kidney 57 
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biopsies in appropriately chosen cases may change the treatment approach and therefore be clinically 58 
relevant in half of the cases with suspected glomerular disease.  59 
To the authors’ knowledge there is currently no published data in the veterinary literature describing the 60 
occurrence of ICGN or primary glomerular disease in the United Kingdom (UK); however, in the authors’ 61 
experience ICGN are not commonly diagnosed in the UK.  62 
The first objective of this study was therefore to investigate the prevalence of ICGN from a large cohort 63 
of dogs originating from the UK where there was clinical suspicion of glomerular disease and where 64 
renal histopathology including routine light microscopy (LM), transmission electron microscopy (TEM) 65 
and immunofluorescence (IF) had been performed. The aim was to be able to better inform clinicians 66 
and owners about the likelihood of a treatment modification (i.e. immunosuppressive therapy) following 67 
renal biopsy.  68 
To date, long-term clinical outcome data in dogs diagnosed with ICGN have not been reported and 69 
despite the logic of immunosuppressive strategies for this disease, there is a lack of published literature 70 
supporting this therapeutic approach.  71 
The second objective of the study was therefore to report prescribed treatment and long-term clinical 72 
outcome of dogs diagnosed with ICGN in the UK.  73 
The third objective of the study was to describe the prevalence, prescribed treatment and survival for 74 
dogs included in the study and not diagnosed with ICGN. 75 
 76 
77 
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Materials and Methods 78 
The study was approved by the Royal Veterinary College Ethical Committee (Social Science Research 79 
Ethical Review Board URN SR2017-1139).  80 
Case selection  81 
The computer database of the International Veterinary Renal Pathology Service (IVRPS; The Ohio State 82 
University – Columbus, Ohio, USA) and European Veterinary Renal Pathology Service (EVRPS; 83 
University of Turin, Italy) were retrospectively searched for canine renal biopsies (including wedge and 84 
needle core biopsy) originating from the UK and submitted from the 1st of January 2010 to the 1st of 85 
September 2017 by a diploma holder in the field of small animal internal medicine (Royal College of 86 
Veterinary Surgeon, American College of Veterinary Internal Medicine or European College of 87 
Veterinary Internal Medicine diploma holder) or by a veterinarian working under the supervision of a 88 
diploma holder in small animal internal medicine. 89 
Inclusion criteria were the presence of persistent and/or severe proteinuria, characterised by a UPC≥0.5 90 
on more than one occasion (Lees et al., 2005) together with a definitive histopathological diagnosis 91 
obtained on the basis of LM, TEM and IF, and the presence of complete signalment, UPC and serum 92 
albumin and creatinine concentrations at the time of diagnosis as well as clinical follow-up until time of 93 
death or until data collection (1st September 2017). Samples obtained post-mortem were excluded. 94 
Due to wide variation in the data reported on submission forms, treatments administered prior to biopsy, 95 
and diet used prior to and following sampling were not recorded. Causes of death were not recorded, 96 
as they were often speculative. Treatment prescribed following renal biopsies and concurrent illnesses 97 
were recorded. 98 
Case follow-up, survival and outcome 99 
The primary veterinarian of each case was contacted by one of the authors to obtain the most recent 100 
follow-up information. Cases were included only if clinical follow-up was available until time of death or 101 
until data collection (1st September 2017) if still alive. There was no minimal follow-up time for the study. 102 
Survival was calculated as the time in days from the date of renal biopsy until the exact date of death or 103 
the study end point (1st September 2017) if still alive.  104 
The number of dogs alive at the study end point, median follow-up time and median survival time of 105 
dogs that died prior to data collection were evaluated and survival times compared between groups .  106 
Follow-up UPC was recorded at variable time points due to non-standardised retrospective data 107 
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collection. For the purposes of this study, therapeutic success in management of ICGN was defined as 108 
a reduction in the UPC by 50% or by achieving a UPC<0.5 (Brown et al., 2013; Segev et al., 2013) at 109 
some point following biopsy. Dogs were considered not to have reached therapeutic success if they 110 
failed to fulfil at least one of these criteria.  111 
Renal biopsy processing, evaluation and classification 112 
All renal biopsies were routinely processed and evaluated by LM, TEM and IF examination as previously 113 
described (Cianciolo et al., 2013) (Cianciolo et al., 2015), by board-certified veterinary histopathologists 114 
working at the IVRPS or at the EVRPS. Classification of renal lesions was based on diagnostic criteria 115 
developed by the World Small Animal Veterinary Association renal biopsy panel (Cianciolo et al., 2015). 116 
Transmission electron microscopy was used as the gold standard method for immune‐complex 117 
detection. Renal biopsies were analysed individually and then grouped into the following disease 118 
categories: immune‐complex‐mediated glomerulonephritis (ICGN), GS, AM, not otherwise specified 119 
glomerulopathies (NOS GP) and other unspecified renal lesions (URL). Not otherwise specified 120 
glomerulopathies (NOS GP) included minimal change disease, podocytopathies and other glomerular 121 
basement membrane abnormalities. Other unspecified renal lesions (URL) included cases for which a 122 
definitive histopathological diagnosis had been reached but did not belong to any of the categories 123 
mentioned earlier, including primary tubulointerstitial disease and non-immune complex mediated 124 
nephropathy..  125 
Statistical analysis 126 
Descriptive statistics are reported. Clinical parameters, survival and duration of follow up are reported 127 
as median (range) (SPSS Statistics®, IBM Corp.). Survival times for dogs grouped according to 128 
glomerular pathology were evaluated using Kaplan-Meier survival curves (SPSS Statistics ®, IBM 129 
Corp.).  130 
131 
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Results 132 
A total of 95 UK cases were identified from the databases. For all cases baseline creatinine, albumin 133 
and UPC were available. Twenty-three cases were excluded because clinical follow-up could not be 134 
obtained. Three cases were excluded because renal biopsies had been obtained post-mortem. These 135 
three cases were diagnosed with thrombotic microangiopathy, a lesion pathognomonic of Cutaneous 136 
and Renal Glomerular Vasculopathy (CRGV) (Holm et al., 2015). Seven additional cases were excluded 137 
as the biopsies obtained were of non-diagnostic quality. Sixty-two dogs were therefore included in the 138 
study.  139 
Signalment 140 
The median age was 8 years (range, 7 months to 15 years). There were 37 males (29 neutered) and 25 141 
spayed females. Twenty-two breeds were represented (Table 1) with Golden Retriever and Labrador 142 
retriever being the most common purebreds (21% total).  143 
Histopathological diagnosis 144 
The most common histopathological diagnosis obtained was GS (35%, 22/62), followed by ICGN (27%, 145 
17/62) (Table 2). Most of the dogs diagnosed with GS were female (68%, 15/22) whereas most of the 146 
dogs diagnosed with ICGN were male (88%, 15/17). Unspecified renal lesions (URL) represented 13% 147 
of the population, with 5 dogs being diagnosed with primary tubulointerstitial disease and 3 dogs with 148 
non-immune complex mediated nephropathy. Clinical data for dogs divided according to renal pathology 149 
diagnosis are presented in Table 2.  150 
Biochemical and urinary abnormalities associated with histopathological diagnosis 151 
In our population, AM was the renal pathology diagnosis associated with the lowest median serum 152 
albumin concentration (15g/L) and the highest magnitude of proteinuria (median UPC 16.6), followed 153 
by ICGN with a median albumin concentration of 20g/L and median UPC of 6.9. The distribution of UPC, 154 
creatinine and albumin are represented for each disease group in Figures 1 a, b, c. 155 
Standard medical management for all dogs undergoing renal biopsy 156 
Following renal biopsy sampling, 52 dogs (84%) were treated with angiotensin-converting enzyme 157 
inhibitors (ACEi), 37 (60%) with antiplatelet agents (19 with clopidogrel, 17 with aspirin, 1 with both), 14 158 
(23%) with amlodipine, 14 (26%) with polyunsaturated fatty acids and 5 (8%) with angiotensin receptor 159 
blockers. Fifteen dogs (24%) received immunosuppressive therapy following sampling (6 prednisolone 160 
only, 4 mycophenolate only, 1 cyclosporine only, 1 azathioprine only, 3 received a combination of 161 
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immune-suppressive drugs). Five of the fifteen dogs treated with immunosuppressive medication did 162 
not belong to the ICGN group and received this medication for another condition (including concurrent 163 
inflammatory bowel disease and non-renal lymphoma).  164 
Treatment for the ICGN group 165 
Seventeen dogs (27%) were diagnosed with ICGN (Table 4) with all but one dog receiving ACEi 166 
treatment following diagnosis. Ten dogs (59%) with ICGN received either single or combined 167 
immunosuppressive therapy (Table 4). All dogs treated with mycophenolate (n=6, including 4 dogs 168 
having received mycophenolate only and 2 dogs having received mycophenolate and chlorambucil) 169 
were alive at the study end point (median follow-up time 712.5 days (range 73-1299), with treatment 170 
success (defined as UPC decreased by 50% or UPC < 0.5) reached in four out of these six dogs (66%). 171 
Mycophenolate dose and treatment duration were not available. No relapse in proteinuria (i.e. increase 172 
to UPC >0.5 or failure to achieve 50% reduction) was documented during the follow-up period for these 173 
4 cases (median follow-up time 734 days, range 73-875 days). Figure 3 shows the progression of UPC 174 
for these four dogs during the first year following diagnosis and treatment. Two of the dogs in the 175 
mycophenolate group also received concurrent chlorambucil therapy, one of which did not achieve 176 
treatment success. The one dog treated with chlorambucil alone reached treatment success and was 177 
still alive at data collection. The one dog treated with azathioprine died 4.5 months following diagnosis. 178 
Seven dogs (41%) with ICGN did not receive any immune-suppressive therapy and only one of them 179 
was alive at the study end point (median survival 302 days (range 52-723)). Three of the seven dogs 180 
(43%) with ICGN that did not receive immunosuppressive therapy achieved a reduction of their UPC by 181 
more than 50% or UPC <0.5 during follow up. All of these dogs were treated with ACEi. 182 
Survival for all dogs undergoing renal biopsy 183 
Survival times are reported in Table 3, and compared between groups in Figure 2.  184 
In our population, renal amyloidosis was associated with the smallest percentage of animals still alive 185 
at data collection (29%) and the shortest median survival time (statistical analyses not performed). One 186 
dog diagnosed with AM, however, was still alive more than 3 years following diagnosis. This dog had a 187 
UPC of 3.9 at the time of diagnosis. 188 
Survival for the ICGN group 189 
In the ICGN group, nine dogs (53%) were still alive at the study end point with a median follow-up time 190 
of 652 days (range, 73-1299), and the median survival time of the eight dogs with ICGN that died prior 191 
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to data collection was 164 days (range, 52-723). Nine of the seventeen dogs (53%) with ICGN had a 192 
reduction of their UPC by more than 50% or reached a UPC <0.5 during the follow-up period.193 
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Discussion 194 
This is the first study to explore the occurrence of ICGN specifically in dogs in the UK using the 195 
combination of LM, TEM and IF for accurate diagnosis.  196 
Similar to the two studies previously published evaluating the prevalence of glomerular disease in the 197 
USA and Europe (Schneider et al., 2013) (Aresu et al., 2017), the Golden Retriever and Labrador 198 
Retriever were the most common breeds represented although both also represent popular breeds in 199 
the UK.  200 
Glomerulosclerosis was the most common diagnosis in dogs undergoing renal biopsy in the UK (35%), 201 
with an occurrence similar to that reported in previous studies (Schneider et al., 2013), (Aresu et al., 202 
2017) and with most dogs being female (68% in this study, 72% in the North American study (Schneider 203 
et al., 2013)). The occurrence of NOS GP and amyloidosis was 13% and 11% respectively, being similar 204 
to previous reports (Schneider et al., 2013), (Aresu et al., 2017).  205 
The study revealed the occurrence of ICGN in dogs undergoing renal biopsy to be lower in the UK 206 
population (27%) when compared to North America (48%) (Schneider et al., 2013) or Europe (including 207 
Mainland Europe and UK altogether ; 50%) (Aresu et al., 2017).  Fifty-three percent of dogs diagnosed 208 
with ICGN in the UK were alive at the study end point with a median follow-up time of 652 days (range 209 
73-1299). Median survival time of dogs that died was 162 days (range 52-723). All dogs treated with 210 
mycophenolate were alive at data collection (median follow-up time 712.5 days (range 73-1299), with 211 
treatment success reached in 4/6 of them. 212 
In this study, most of the dogs diagnosed with ICGN were male (88%). This seems to differ from previous 213 
results, as only 45% of dogs diagnosed with ICGN in North America were males (Schneider et al., 2013).  214 
The seemingly lower percentage of ICGN diagnosed in dogs undergoing renal biopsy for possible 215 
glomerular disease in the UK may be due to a lower prevalence of ICGN in the general UK canine 216 
population. This may be explained by a lower prevalence of infectious diseases in this country compared 217 
to North America and Mainland Europe. Membranoproliferative glomerulonephritis (MPGN) is 218 
considered one of the most common causes of ICGN in dogs with a reported prevalence of 26-60% 219 
(Macdougall et al., 1986) (Koeman et al.,1987) (Cianciolo et al., 2015) and is mainly induced by 220 
infectious diseases with immune complex accumulation on the sub-endothelial side of the glomerular 221 
basement membrane (Vaden, 2017). Dirofilaria immitis (Nakagaki et al., 1993), Leishmania infantum 222 
(Aresu et al., 2013) (Zatelli et al., 2003), Babesia spp. (Wozniak et al., 1997) (Máthé et al., 2007) and 223 
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other tick borne diseases (IRIS Glomerular Study Group et al., 2013) and systemic fungal diseases such 224 
as Coccidioides spp. (Mehrkens et al., 2016) have been associated with the development of ICGN and 225 
are non-existent to rare in the UK unless the patient has a travel history (Johnson, 2016) (Crawford et 226 
al., 2013) (Genchi et al., 2014) (Silvestrini et al., 2016). However, Borrelia burgdorferi is present in the 227 
UK (Shaw et al., 2005) and has also been reported as an inciting cause for ICGN, although its 228 
importance remains controversial (Hutton et al., 2008). Due to the retrospective nature of this study, 229 
infectious disease screening was not standardised and the travel history and infectious disease status 230 
of many cases in the current study was unknown. However, it is possible that dogs from the UK will less 231 
commonly develop infection-induced ICGN.  232 
The different percentage of ICGN diagnosed in dogs undergoing renal biopsy for possible glomerular 233 
disease in the UK may also be explained by the low number of cases included in this study, or by a 234 
difference in inclusion criteria between studies. Inclusion criteria for the study performed in North 235 
America were the following: dogs with a history of nephritic syndrome, nephrotic syndrome, or 236 
glomerulonephritis, or a UPC>2, or persistent renal proteinuria (proteinuria identified on routine 237 
urinalysis with or without UPC >0.5 on multiple occasions in the absence of prerenal or postrenal causes 238 
for proteinuria) (Schneider et al., 2013). Inclusion criteria for the study performed in Europe was any 239 
renal biopsy specimen interpreted by LM and TEM (Aresu et al., 2017). One of the inclusion criteria for 240 
the current study was UPC≥0.5 on more than one occasion (Lees et al., 2005). Although 0.5 is 241 
considered as the upper reference for canine UPC, this criteria may represent a selection bias, because 242 
some clinicians would consider kidney biopsies only when UPC>2 or above. The current study only 243 
included cases with available follow-up, which once again was not the case for previously reported 244 
studies. These disparities between inclusion criteria represent a limitation to ICGN occurrence 245 
comparison.  246 
Finally, cases for the North American study were retrospectively collected between 2007 and 2012 247 
(Schneider et al., 2013). It is possible that recommendations issued in the 2013 IRIS proteinuria 248 
consensus statement (Littman et al., 2013) raised awareness around ICGN and increased the number 249 
of kidney biopsies performed, modifying the population of dogs undergoing renal biopsies. Although 250 
statistical analyses were not performed, there was an overlap in the UPC, albumin and creatinine 251 
concentrations between different histopathological diagnoses in this study, such that none of these 252 
parameters appeared to be possibly used to discriminate between underlying glomerular disease 253 
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conditions. This confirms, as previously documented by Schneider and colleagues (2013), the 254 
requirement to obtain renal biopsies in order to determine whether immune complex deposits are 255 
present prior to potentially pursuing immunosuppressive therapy in these dogs.  256 
To the author’s knowledge, this is the first study reporting the long-term outcome of a group of dogs 257 
diagnosed with ICGN. Out of the 17 cases diagnosed with ICGN, more than half were still alive at data 258 
collection with a median follow-up time of 652 days (range 73-1299). When long-term outcome was 259 
compared between disease groups in our population, NOS GP was the group with the longest median 260 
survival time and median follow-up time, followed by ICGN and GS. In our study, renal AM was 261 
associated with the worst prognosis, with only 29% of animals alive at time of data collection and a 262 
median survival time of less than 5 months. A previous study comparing dogs diagnosed with glomerular 263 
disease and nephrotic syndrome (NS) versus dogs diagnosed with non-nephrotic glomerular disease 264 
(NNGD) reported a median survival time of 12.5 days for dogs with NS versus 104.5 days for dogs with 265 
NNGD dogs (Klosterman et al., 2011). Less than half of the dogs described in that study underwent 266 
renal biopsies, therefore definitive histopathological diagnosis was not reached and direct comparison 267 
with our results is difficult. Overall, it would appear that survival times were longer in our study compared 268 
to that study.   269 
IRIS current recommendation for histopathologically diagnosed ICGN in dogs states the following 270 
(Segev et al., 2013) : “for diseases associated with profound proteinuria, attendant hypoalbuminaemia, 271 
nephrotic syndrome, or rapidly progressive azotaemia, single drug or combination therapy consisting of 272 
rapidly acting immunosuppressive drugs is recommended. The Study Group recommends 273 
mycophenolate alone or in combination with prednisolone. For stable or slowly progressive glomerular 274 
diseases, the Study Group recommends mycophenolate or chlorambucil alone or in combination with 275 
azathioprine on alternating days”. In this study, seven dogs in the ICGN group (42%) did not receive 276 
any immune-suppressive therapy, and only one of these was alive at the time of data collection. It is 277 
interesting to note that 43% of dogs diagnosed with ICGN that did not receive immunosuppressive 278 
therapy achieved a UPC<0.5 or a reduction of their UPC by more than 50% following biopsy, highlighting 279 
that in some cases, ICGN (or ICGN-induced proteinuria) may be self-resolving and/or controlled by 280 
blockade of the renin angiotensin aldosterone system and nutrition adjustment (reduced n6/n3 281 
polyunsaturated fatty acid ratio, protein restriction) as recommended by the IRIS proteinuria consensus 282 
statement (Brown et al., 2013). Due to the retrospective nature of the study it is not possible to ascertain 283 
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why immunosuppressive therapy was not prescribed in these dogs, for example if there was concurrent 284 
concern for an infectious aetiology that required treatment.  285 
Six dogs with ICGN were treated with mycophenolate (n=2 with concurrent chlorambucil), all of which 286 
were alive at data collection, with treatment success reached in 4/6 of the dogs within 6 months. The 287 
dogs in this study were included retrospectively and also received other medication such as ACEi which 288 
may have contributed to the reduction of their UPC. It is therefore impossible to know whether a similar 289 
positive response would have occurred with other immunosuppressive agents in these dogs or whether 290 
the positive response is specifically related to the use of mycophenolate. Repeated renal biopsies (or 291 
post-mortem examination) were not performed for any of the cases in this study but would provide further 292 
information regarding disease resolution or progression in response to treatment. Relationship between 293 
treatment and survival were not statistically analysed considering the low number of cases per group, 294 
therefore it is unknown if mycophenolate improves the outcome of dogs diagnosed with ICGN. 295 
Limitations of the study include its retrospective nature, the low number of dogs included, lack of 296 
information regarding travel history of included cases, treatment prior to biopsy, concurrent diseases 297 
and unknown cause of death, as well as the lack of standardised protocols for investigations prior to 298 
biopsy, treatment and follow-up. As an example, the UPC follow-up over-time was only available and 299 
therefore described for dogs diagnosed with ICGN, treated with mycophenolate and that responded to 300 
treatment. Clinico-pathological results included in this study were obtained from a number of different 301 
diagnostic laboratories, although interpretation of renal pathology was performed by veterinary 302 
nephropathologists (LA and RC).  303 
Having considered these limitations, the data obtained in this study is informative for clinicians practising 304 
within the UK when presented with dogs with proteinuria that is considered likely to be glomerular in 305 
origin. Where possible, renal biopsy should be considered in order to document the presence of ICGN 306 
prior to considering immunosuppressive therapy, particularly given the apparently lower occurrence of 307 
ICGN in the UK population of dogs with glomerular disease. Furthermore, it is important to discuss with 308 
owners the fact that renal biopsies would lead to a different therapeutic strategy in approximately a 309 
quarter of cases. Nevertheless, for those dogs where ICGN is identified, owners should be counselled 310 
that long-term outcomes could be favourable. Further study is warranted to further differentiate the 311 
underlying aetiology of ICGN, location of immune-complex deposition and whether different 312 
immunosuppressive treatment strategies may be beneficial.   313 
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Conclusion 314 
This study revealed that the occurrence of ICGN might be lower in the UK than previously reported in 315 
North America and mainland Europe, which may influence clinician’s decisions in terms of renal biopsy 316 
and/or treatment. The prognosis associated with ICGN appears overall fair, and from this data 317 
mycophenolate is the most commonly used immunosuppressive drug.   318 
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Figures legend:  319 
 320 
Table 1. Breeds of dogs biopsied for evaluation of suspected glomerular disease 321 
 322 
Table 2. Histopathological diagnosis, urine and serum biochemical abnormalities of dogs biopsied for 323 
evaluation of suspected glomerular disease 324 
GS: glomerulosclerosis, ICGN: immune-complex glomerulonephritis, NOS GP: not otherwise specified 325 
glomerulopathies, AM: amyloidosis, URL: unspecified renal lesion, UPC: urinary protein-to-creatinine 326 
ratio 327 
 328 
Table 3. Median survival time and median follow-up time per disease group 329 
n: number, GS: glomerulosclerosis, ICGN: immune-complex glomerulonephritis, NOS GP: not otherwise 330 
specified glomerulopathies, AM: amyloidosis, URL: unspecified renal lesion 331 
 332 
Table 4. Signalment, clinico-pathological abnormalities at the time of diagnosis, treatment and outcome 333 
of the 17 cases diagnosed with ICGN 334 
UPC: urinary protein-to-creatinine ratio 335 
 336 
Figure 1a. UPC ratios for each disease group  337 
Figure 1b. Creatinine concentrations for each disease group 338 
Figure 1c. Albumin concentrations for each disease group 339 
GS: glomerulosclerosis, ICGN: immune-complex glomerulonephritis, NOS GP: not otherwise specified 340 
glomerulopathies, AM: amyloidosis, URL: unspecified renal lesion, UPC: urinary protein-to-creatinine 341 
ratio 342 
 343 
Figure 2. Kaplan Meyer survival curves for dogs that have undergone renal biopsy according to 344 
underlying pathology identified 345 
GS: glomerulosclerosis, ICGN: immune-complex glomerulonephritis, NOS GP: not otherwise specified 346 
glomerulopathies, AM: amyloidosis, URL: unspecified renal lesion 347 
 348 
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Figure 3. Longitudinal evaluation of UPC values for the four dogs diagnosed with ICGN, treated with 349 
mycophenolate and that responded to treatment for the first 12 months period after renal biopsy  350 
UPC: urinary protein-to-creatinine ratio 351 
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